Avalyn Pharma Stock
Avalyn Pharma Inc. Common Stock
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Lyn Baranowski
- Employees
- 55
- Market cap
- $1 B
- IPO
- 30/04/2026
Avalyn Pharma Inc. is a biopharmaceutical company operating within the biotechnology sector. Headquartered in Boston, USA, the firm is currently in its clinical development phase. The primary focus of Avalyn Pharma Inc. is the creation of inhaled pharmaceutical products designed to manage rare lung conditions. This…
Company description based on the data provider's company data, AI-assisted, created on 17/10/2026. Not investment advice.
Avalyn Pharma stock: price history
1D
-4.0%
1W
-8.2%
1M
-31.8%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
Not enough history for an assessment
Ask the agents about Avalyn Pharma
Analyst assessment of Avalyn Pharma
PRICE TARGET LOW
US$51.00
CONSENSUS
US$60.00
MEDIAN
US$57.00
PRICE TARGET HIGH
US$80.00
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 13/08/2026
Avalyn Pharma stock metrics
P/E
-18.34
P/B
2.63
EV/EBITDA
-13.85
RETURN ON EQUITY
-7.3%
NET MARGIN
0.0%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
32.6%
FLOAT SHARES
14,454,887
AVG. DAILY VOLUME (30D)
308,955
Insider transactions (SEC)
FMR LLC
FMR LLC
FMR LLC
FMR LLC
FMR LLC
Institutional holders
Comparable stocks
Frequently asked questions about Avalyn Pharma stock
What does Avalyn Pharma do?
Avalyn Pharma Inc. Common Stock is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Lyn Baranowski, the company employs around 55 people.
The IPO was on 30/04/2026; the stock trades on NASDAQ under the ticker AVLN.
What do analysts say about Avalyn Pharma stock?
1 analysts rate the stock, the consensus is Buy (as of 13/08/2026).
The average price target is US$60.00, ranging from US$51.00 to US$80.00, with a median of US$57.00.
This is an external assessment, not a statement by Market Jury.
When does Avalyn Pharma report next?
The next earnings date is 11/11/2026.
Does Avalyn Pharma pay a dividend?
No, Avalyn Pharma currently does not pay a dividend.
Which stocks are comparable to Avalyn Pharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Avalyn Pharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Avalyn Pharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.